AC Immune SA
ACIU
$2.20
-$0.08-3.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 91.38% | 95.15% | 88.56% | 4,693,860.00% | 329.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.38% | 95.15% | 88.56% | 4,693,860.00% | 329.09% |
| Cost of Revenue | 8.88% | 13.02% | 16.80% | 15.99% | 9.96% |
| Gross Profit | 20.30% | 16.54% | 10.41% | 62.26% | 12.94% |
| SG&A Expenses | -3.53% | 3.12% | 15.04% | 18.49% | 19.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 92.81% | 93.64% | 90.27% | 67.26% | 33.50% |
| Total Operating Expenses | 7.25% | 12.48% | 18.73% | 18.40% | 12.91% |
| Operating Income | 14.48% | 9.31% | 0.90% | 44.28% | 5.14% |
| Income Before Tax | 14.13% | 5.99% | 4.86% | 39.95% | 4.23% |
| Income Tax Expenses | -24.44% | -56.41% | -69.09% | -90.83% | -64.57% |
| Earnings from Continuing Operations | 14.13% | 5.99% | 4.87% | 39.96% | 4.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.13% | 5.99% | 4.87% | 39.96% | 4.24% |
| EBIT | 14.48% | 9.31% | 0.90% | 44.28% | 5.14% |
| EBITDA | 14.67% | 9.27% | 0.62% | 45.25% | 5.20% |
| EPS Basic | 19.42% | 16.10% | 19.28% | 48.30% | 14.78% |
| Normalized Basic EPS | 19.42% | 16.09% | 19.27% | 48.30% | 14.78% |
| EPS Diluted | 18.34% | 14.99% | 18.19% | 47.72% | 14.61% |
| Normalized Diluted EPS | 19.33% | 16.00% | 19.18% | 48.22% | 14.78% |
| Average Basic Shares Outstanding | 8.23% | 12.47% | 17.39% | 14.55% | 10.42% |
| Average Diluted Shares Outstanding | 8.50% | 12.76% | 17.69% | 14.85% | 10.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |